drugset
drugset / Trial / NCT00762346

Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis

NCT00762346 ↗

Phase 4 Completed 156 enrolled Sun Yat-sen University Novartis · collab
NaSingle-groupOpen-labelTreatment

Summary

A multicenter prospective study to assess the efficacy and safety of ZOMETA® in treatment of high-level NTX non small cell lung cancer with bone metastasis.

Timeline

Start
2008-09
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified 4 mg Intravenous

Indications

metastatic carcinoma in the bone non-small cell lung carcinoma